Supernus Pharmaceuticals Shares Outstanding 2011-2024 | SUPN
Supernus Pharmaceuticals shares outstanding from 2011 to 2024. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Supernus Pharmaceuticals Annual Shares Outstanding
(Millions of Shares) |
| 2023 |
56 |
| 2022 |
62 |
| 2021 |
54 |
| 2020 |
54 |
| 2019 |
54 |
| 2018 |
54 |
| 2017 |
53 |
| 2016 |
52 |
| 2015 |
51 |
| 2014 |
42 |
| 2013 |
32 |
| 2012 |
17 |
| 2011 |
2 |
| 2010 |
2 |
Supernus Pharmaceuticals Quarterly Shares Outstanding
(Millions of Shares) |
| 2024-09-30 |
56 |
| 2024-06-30 |
56 |
| 2024-03-31 |
56 |
| 2023-12-31 |
56 |
| 2023-09-30 |
55 |
| 2023-06-30 |
55 |
| 2023-03-31 |
62 |
| 2022-12-31 |
62 |
| 2022-09-30 |
55 |
| 2022-06-30 |
61 |
| 2022-03-31 |
61 |
| 2021-12-31 |
54 |
| 2021-09-30 |
54 |
| 2021-06-30 |
55 |
| 2021-03-31 |
54 |
| 2020-12-31 |
54 |
| 2020-09-30 |
54 |
| 2020-06-30 |
54 |
| 2020-03-31 |
54 |
| 2019-12-31 |
54 |
| 2019-09-30 |
54 |
| 2019-06-30 |
54 |
| 2019-03-31 |
54 |
| 2018-12-31 |
54 |
| 2018-09-30 |
54 |
| 2018-06-30 |
54 |
| 2018-03-31 |
54 |
| 2017-12-31 |
53 |
| 2017-09-30 |
54 |
| 2017-06-30 |
53 |
| 2017-03-31 |
53 |
| 2016-12-31 |
52 |
| 2016-09-30 |
52 |
| 2016-06-30 |
52 |
| 2016-03-31 |
51 |
| 2015-12-31 |
51 |
| 2015-09-30 |
52 |
| 2015-06-30 |
52 |
| 2015-03-31 |
45 |
| 2014-12-31 |
42 |
| 2014-09-30 |
43 |
| 2014-06-30 |
42 |
| 2014-03-31 |
41 |
| 2013-12-31 |
32 |
| 2013-09-30 |
31 |
| 2013-06-30 |
31 |
| 2013-03-31 |
31 |
| 2012-12-31 |
17 |
| 2012-09-30 |
24 |
| 2012-06-30 |
17 |
| 2012-03-31 |
2 |
| 2011-12-31 |
2 |
| 2011-09-30 |
2 |
| 2011-06-30 |
2 |
| 2011-03-31 |
2 |
| 2010-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.962B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
